$0.50
+0.02 (+4.10%)
USD · as of 2026-08-18 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where KTTA is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
2 interventional
Held by 2 tracked-famous managers (RENAISSANCE TECHNOLOGIES LLC, TWO SIGMA INVESTMENTS, LP) · FINRA short interest 1.0 days to cover (settled 2026-07-31) · insider 90d: 1 buys / 0 sells · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| PAS-004 in Adults Who Have Neurofibromatosis Type 1 With Plexiform NeurofibromasNCT06961565Part A: To evaluate the safety and tolerability of PAS-004 when administered for one 28-day treatment cycleNon-randomized · Open-label · Treatment | Phase 1 | Recruiting | Drug: PAS-004 Tablets | NF1 Mutation, Neurofibroma Plexiform, Neurofibroma, Plexiform, Neurofibromatosis Type 1 (NF1)-Related Plexiform Neurofibromas (PNs), Neurofibromatosis Type 1 (NF1) | 56 | Sep 2027 | ≤ 407 d | 2025-12-04 |
| PAS-004 in Patients With Advanced Solid TumorsNCT06299839Evaluation of dose limiting toxicities (DLTs)Non-randomized · Open-label · Treatment | Phase 1 | Recruiting | Drug: PAS-004 Capsules, PAS-004 Tablets | RAS Mutation, NF1 Mutation, RAF Mutation, Advanced Solid Tumors | 48 | Feb 2026 | — | 2025-12-03 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19